Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
4
×
Tags
boston blog main
4
×
boston top stories
clinical trials
fda
life sciences
national blog main
national top stories
new york blog main
new york top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
4
×
akcea therapeutics
alnylam pharmaceuticals
biotech
boston
boulder/denver blog main
boulder/denver top stories
cancer
detroit blog main
detroit top stories
drugs
hereditary transthyretin amyloidosis
indiana blog main
indiana top stories
inotersen
national
patisiran
raleigh-durham blog main
raleigh-durham top stories
rna interference
seattle blog main
seattle top stories
tafamidis
texas blog main
texas top stories
vyndaqel
wisconsin blog main
wisconsin top stories
What
fda
4
×
medicine
4
×
drug
alnylam
approved
cancer
patients
time
afternoon
ago
alnylam’s
approve
awaits
biological
crossed
decades
decision
deeper
discovered
dna
eisai
fingerprint
fingers
flags
friday
genetic
gets
going
higher
historic
history
incidence
landmark
lorcaserin
loss
making
market
marketing
matter
nd
Language
unset
Current search:
photo
×
fda
×
" san francisco top stories "
×
" boston blog main "
×
medicine
×
@xconomy.com
4 years ago
Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks
@xconomy.com
5 years ago
Genetic Medicine: FDA OKs 2nd Cancer Drug that Targets DNA, not Tissues
@xconomy.com
5 years ago
Alnylam Gets Landmark FDA OK For First-Ever RNAi Drug
@xconomy.com
5 years ago
Patients Have “Fingers Crossed” As Alnylam Awaits Historic FDA Decision